Kazia - KZIA Enterprise Value-to-Sales Ratio

Official company branding of Kazia Therapeutics Ltd (KZIA)

Demand for neuro-oncology solutions remains independent of economic cycles, as brain therapy is critically important. Kazia Therapeutics (KZIA) is developing breakthrough small molecules for precision cancer treatment. This EV/Sales multiple chart helps identify speculative overvaluation of the business, with the current level standing at 368000.00. However, the R&D stage limits scaling, leading to linear growth in clinical trial costs.

Kazia Therapeutics Limited (KZIA): Company Value to Revenue from 11/23/2025 to 11/20/2026

Kazia Therapeutics Limited - analytical breakdowns and key metrics (KZIA)

- cash balance and cash flow data:
Fundamental company valuation:KZIA, Kazia
Manufactured products of kaziatherapeutics.com

A technological barrier in the form of a patent for a glioblastoma drug determines the fundamental stability of Kazia Therapeutics (KZIA). By analyzing the EV/Sales multiple, an investor assesses the total enterprise value relative to revenue excluding debt, which allows for the determination of overpayment for future sales and the comparison of market capitalization with the company's actual financial resources under constrained budget conditions.